Aeglea Biotherapeutics Inc. (AGLE)
$11.33
Insights on Aeglea Biotherapeutics Inc.
Increasing Revenue
Revenue is up for the last 3 quarters, 168.0K → 688.0K (in $), with an average increase of 43.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -18.49M → -217.08M (in $), with an average decrease of 1073.8% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 91.4% return, outperforming this stock by 93.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 165.8% return, outperforming this stock by 259.4%
Performance
- $11.01$12.31$11.33
2.82%
Downside
Day's Volatility :10.56%
Upside
7.96%
- $2.66$39.00$11.33
76.52%
Downside
52 Weeks Volatility :93.18%
Upside
70.95%
Returns
| Period | Aeglea Biotherapeutics Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 20.85% | -0.9% | 0.0% |
6 Months | 48.54% | 1.5% | 1.0% |
1 Year | -1.56% | 7.1% | 6.4% |
3 Years | -93.68% | 25.9% | 19.9% |
Highlights
Market Capitalization | 47.1M |
Book Value | - $64.0 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -72.16 |
PEG Ratio | 0.0 |
Wall Street Target Price | 17.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -16695.2% |
Return On Assets TTM | -73.17% |
Return On Equity TTM | -163.26% |
Revenue TTM | 1.2M |
Revenue Per Share TTM | 0.32 |
Quarterly Revenue Growth YOY | 10.100000000000001% |
Gross Profit TTM | -262.0K |
EBITDA | -203.5M |
Diluted Eps TTM | -72.16 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -34.97 |
EPS Estimate Next Year | -6.78 |
EPS Estimate Current Quarter | -0.18 |
EPS Estimate Next Quarter | -0.02 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 56.66%
Technicals Summary
Sell
Neutral
Buy
Aeglea Biotherapeutics Inc. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Aeglea Biotherapeutics Inc. | -14.7% | 48.54% | -1.56% | -93.68% | -95.26% |
 Moderna, Inc. | -13.8% | -33.86% | -19.73% | 39.08% | 427.53% |
 Regeneron Pharmaceuticals, Inc. | 0.18% | 1.46% | 19.77% | 45.55% | 105.03% |
 Novo Nordisk A/s | -2.09% | 18.67% | 91.43% | 165.4% | 285.43% |
 Seagen, Inc. | 4.8% | 8.3% | 59.7% | 13.46% | 176.24% |
 Vertex Pharmaceuticals Incorporated | 0.03% | 14.01% | 23.51% | 31.36% | 85.35% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Aeglea Biotherapeutics Inc. | NA | NA | 0.0 | -34.97 | -1.63 | -0.73 | 0.0 | -64.0 |
Moderna, Inc. | 35.31 | 35.31 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
Regeneron Pharmaceuticals, Inc. | 21.73 | 21.73 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
Novo Nordisk A/s | 42.99 | 42.99 | 2.03 | 1.65 | 0.82 | 0.22 | 0.01 | 2.52 |
Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
Vertex Pharmaceuticals Incorporated | 27.12 | 27.12 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Aeglea Biotherapeutics Inc. | Buy | $47.1M | -95.26% | NA | 0.0% |
Moderna, Inc. | Buy | $37.4B | 427.53% | 35.31 | 11.33% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.4B | 105.03% | 21.73 | 33.93% |
Novo Nordisk A/s | Buy | $407.6B | 285.43% | 42.99 | 33.4% |
Seagen, Inc. | Hold | $40.6B | 176.24% | NA | -33.55% |
Vertex Pharmaceuticals Incorporated | Buy | $90.8B | 85.35% | 27.12 | 35.4% |
Institutional Holdings
Fairmount Funds Management LLC
9.35%Wellington Management Company LLP
8.72%VR Adviser, LLC
6.27%EcoR1 Capital, LLC
4.94%Affinity Asset Advisors, LLC
4.84%Driehaus Capital Management LLC
4.59%
Corporate Announcements
Aeglea Biotherapeutics Inc. Earnings
Aeglea Biotherapeutics Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Organization | Aeglea Biotherapeutics Inc. |
Employees | 14 |
CEO | Dr. Leslie S. Sloan Ph.D. |
Industry | Health Technology |
